Thrombin-directed inhibitors: Pharmacology and clinical use

被引：26

作者：

White, CM ^{[1
]}

机构：

[1] Univ Connecticut, Hartford Hosp, Ishikari, Hokkaido 06102, Japan

来源：

AMERICAN HEART JOURNAL | 2005年 / 149卷 / 01期

关键词：

D O I：

10.1016/j.ahj.2004.10.023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：S54 / S60

页数：7

共 34 条

[1]

ARGATROBAN, 2000, SMITHKLINE BEECHAM P

[2]

Eichler P, 2000, BLOOD, V96, P2373

[3] Prevention of venous thromboembolism following orthopaedic surgery - Clinical potential of direct thrombin inhibitors [J].

Eriksson, BI ;

Dahl, AE .

DRUGS, 2004, 64 (06) :577-595

[4] Ximelagatran/melagatran - A review of its use in the prevention of venous thromboembolism in orthopaedic surgery [J].

Evans, HC ;

Perry, CM ;

Faulds, D .

DRUGS, 2004, 64 (06) :649-678

[5]

FOX I, 1993, THROMB HAEMOSTASIS, V69, P157

[6] Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery:: incidence and clinical relevance [J].

Greinacher, A ;

Eichler, P ;

Albrecht, D ;

Strobel, U ;

Pötzsch, B ;

Eriksson, BI .

BLOOD, 2003, 101 (07) :2617-2619

[7] Recombinant hirudin in clinical practice - Focus on lepirudin [J].

Greinacher, A ;

Lubenow, N .

CIRCULATION, 2001, 103 (10) :1479-1484

[8] The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: A mini-review [J].

Gustafsson, D ;

Elg, M .

THROMBOSIS RESEARCH, 2003, 109 :S9-S15

[9]

HANSTEN PD, 2002, 100 DRUG INTERACTION

[10] Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia [J].

Harenberg, J ;

Huhle, G ;

Wang, LC ;

Hoffmann, U ;

Song, XH .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (02) :360-363

← 1 2 3 4 →